Updates are available Correction dated 2023-04-03
Click to view Correction: https://doi.org/10.1038/s43018-023-00549-4
-
Authors
Onkar, Sayali
Cui, Jian
Zou, Jian
Cardello, Carly
Cillo, Anthony R. https://orcid.org/0000-0002-3213-3129
Uddin, Mostofa Rafid
Sagan, April https://orcid.org/0000-0001-6467-3958
Joy, Marion
Osmanbeyoglu, Hatice U.
Pogue-Geile, Katherine L.
McAuliffe, Priscilla F.
Lucas, Peter C.
Tseng, George C.
Lee, Adrian V.
Bruno, Tullia C. https://orcid.org/0000-0002-6433-0207
Oesterreich, Steffi https://orcid.org/0000-0002-2537-6923
Vignali, Dario A. A. https://orcid.org/0000-0002-2771-5992
- License Information
-
More Information
Article History
Received: 7 January 2022
Accepted: 10 February 2023
First Online: 16 March 2023
Change Date: 3 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-023-00549-4
Competing interests
: D.A.A.V. discloses the following conflicts: cofounder and stockholder: Novasenta, Potenza, Tizona and Trishula; stockholder: Oncorus and Werewolf; patents licensed and royalties: Astellas, BMS and Novasenta; scientific advisory board member: Tizona, Werewolf, F-Star, Bicara, Apeximmune and T7/Imreg Bio; consultant: Astellas, BMS, Almirall, Incyte, G1 Therapeutics, Inzen Therapeutics, Regeneron and Avidity Partners; research funding: BMS and Novasenta. All authors declare no competing financial or non-financial interests in relation to the work submitted in this paper.
